Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2023 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 29, 2023 08:15 ET | Source: BioCardia, Inc.

BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 16, 2023 07:00 ET | Source: BioCardia, Inc.

BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023

SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 06, 2023 07:00 ET | Source: BioCardia, Inc.

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years Results Suggest CardiAMP Cell Therapy May Have Ability to Restore and Maintain Heart...
February 01, 2023 06:30 ET | Source: BioCardia, Inc.

BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

SUNNYVALE, Calif. and MULHOUSE, France, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular...
December 22, 2022 07:00 ET | Source: BioCardia, Inc.

BioCardia Letter to Shareholders

SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and...
December 15, 2022 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces $3.6 Million Private Placement of Common Stock

SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and...
November 09, 2022 16:05 ET | Source: BioCardia, Inc.

BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
November 02, 2022 17:31 ET | Source: BioCardia, Inc.

BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022

SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
October 03, 2022 07:00 ET | Source: BioCardia, Inc.

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right